Clinical characteristics of overseas imported and related local COVID-19 patients in Chengdu_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZOU Liping ¹ , MAO Yi ¹ , LUO Haixia ¹ , CHEN Zhu ¹ , JIANG Hong ¹ , LI Maoying ¹ ,  WU Guihui ² ,  WEI Jiafu ³

1. Department of Emergency, Chengdu Public Health Clinical Medical Center, Chengdu, 610066, P.R.China;
2. Department of Tuberculosis, Chengdu Public Health Clinical Medical Center, Chengdu, 610066, P.R.China;
3. Cardiovascular Medicine Department, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

WU Guihui, Email: Wghwgh2584@sina.com; WEI Jiafu, Email: weijiafu@163.com

Keywords：

Coronavirus disease 2019; overseas imported; local patients; clinical characteristics

DOI：

10.7507/1007-4848.202102042

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the clinical characteristics of overseas imported and related local COVID-19 patients in Chengdu.Methods Fifty overseas imported patients who were Chinese and 14 related local patients with COVID-19 who were admitted to Public Health Clinical Center of Chengdu from November to December 2020 were selected. The epidemiological characteristics, clinical manifestations, auxiliary examination, treatment and prognosis were summarized and analyzed.Results The local group were older, and they were mostly elderly and females (P≤0.05). Compared with the imported group, the proportion of the local group was higher in heart disease and tumor. More patients had cough, fever and expectoration symptoms (P≤0.05). C-reactive protein, fasting blood glucose and fibrinogen were higher, and the lymphocyte count, blood platelet count, CD3⁺ T lymphocyte count, CD4⁺ T lymphocyte count, CD8⁺ T lymphocyte count were lower. The positive rate of novel coronavirus total antibody, IgG antibody and IgM antibody in the imported group were higher than those in the local group (P≤0.05). The negative conversion time of the median nucleic acid was shorter than that of local patients (P≤0.05).Conclusion There are differences in sex ratio, age, complications, clinical manifestations, lymphocyte measurement value, T lymphocyte count and negative conversion time of nucleic acid between overseas imported and local COVID-19 patients in Chengdu. The local patients are mostly elderly and have more complicated conditions, but all of them have good prognosis.

Citation： ZOU Liping, MAO Yi, LUO Haixia, CHEN Zhu, JIANG Hong, LI Maoying, WU Guihui, WEI Jiafu. Clinical characteristics of overseas imported and related local COVID-19 patients in Chengdu. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(9): 1021-1028. doi: 10.7507/1007-4848.202102042 Copy

1.	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2.	World Health Organization. Coronavirus. [2021-02-03] https://www.who.int/health-topics/coronavirus.
3.	國家衛生健康委員會, 國家中醫藥管理局. 新型冠狀病毒肺炎診療方案 (試行第八版). [2020-08-19] http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml.
4.	國務院應對新型冠狀病毒肺炎疫情聯防聯控機制綜合組. 新型冠狀病毒肺炎防控方案 (第七版). [2020-09-11] http://www.gov.cn/xinwen/2020-09/15/content_5543680.htm.
5.	Gupta R, Ghosh A, Singh AK, et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr, 2020, 14(3): 211-212.
6.	Yamamoto N, Bauer G. Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation. Med Hypotheses, 2020, 144: 110160.
7.	中華醫學會呼吸病學分會, 中國醫師協會呼吸醫師分會. 中國成人2019冠狀病毒病的診治與防控指南. 中華醫學雜志, 2021, 101(18): 1293-1356.
8.	Islam OK, Al-Emran HM, Hasan MS, et al. Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia. Transbound Emerg Dis, 2021, 68(2): 824-832.
9.	Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill, 2021, 26(1): 2002106.
10.	Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol, 2020, 127: 104378.
11.	Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ, 2020, 369: m1985.
12.	陳竹, 毛毅, 陳霆, 等. 成都379例新型冠狀病毒肺炎的臨床分析. 中國胸心血管外科臨床雜志, 2021, 28(4): 388-395.
13.	Joyce KE, Weaver SR, Lucas SJE. Geographic components of SARS-CoV-2 expansion: A hypothesis. J Appl Physiol (1985), 2020, 129(2): 257-262.
14.	Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84.
15.	郝耀梅, 任建業. 慢性病患者用藥依從性管理案例分析. 中國藥物與臨床, 2021, 21(4): 685-686.
16.	Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: Results from the china hypertension survey, 2012-2015. Circulation, 2018, 137(22): 2344-2356.
17.	Nikolich-?ugich J. The twilight of immunity: Emerging concepts in aging of the immune system. Nat Immunol, 2018, 19(1): 10-19.
18.	Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: An observational cohort study. Lancet, 2020, 396(10251): 603-611.
19.	李聞, 鄭寶璐, 于愛萍, 等. 新型冠狀病毒IgM/IgG抗體在病程監測中的臨床意義. 臨床檢驗雜志, 2020, 38(6): 401-404.
20.	馬春娜, 吳雙勝, 孫瑛, 等. 2020年1~7月北京市不同階段新型冠狀病毒肺炎疫情特征分析. 國際病毒學雜志, 2020, 27(6): 448-454.
21.	陳晴, 黃濤, 楊銘, 等. 成都市不同年齡段新型冠狀病毒肺炎患者臨床特征及預后分析. 實用心腦肺血管病雜志, 2020, 28(12): 9-15.
22.	Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
23.	Shi P, Ren G, Yang J, et al. Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: A multicentre retrospective study. Epidemiol Infect, 2020, 148: e238.
24.	代嫣嫣, 夏帥, 王茜, 等. 人類高致病性冠狀病毒SARS-CoV和MERS-CoV的流行與突變—共性與個性特征的啟示. 生命科學, 2016, 28(3): 357-366.
25.	Khan MI, Khan ZA, Baig MH, et al. Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight. PLoS One, 2020, 15(9): e0238344.
26.	Rabaan AA, Al-Ahmed SH, Sah R, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob, 2020, 19(1): 40.
27.	Dhama K, Patel SK, Pathak M, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis, 2020, 37: 101755.

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
2. World Health Organization. Coronavirus. [2021-02-03] https://www.who.int/health-topics/coronavirus.
3. 國家衛生健康委員會, 國家中醫藥管理局. 新型冠狀病毒肺炎診療方案 (試行第八版). [2020-08-19] http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml.
4. 國務院應對新型冠狀病毒肺炎疫情聯防聯控機制綜合組. 新型冠狀病毒肺炎防控方案 (第七版). [2020-09-11] http://www.gov.cn/xinwen/2020-09/15/content_5543680.htm.
5. Gupta R, Ghosh A, Singh AK, et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr, 2020, 14(3): 211-212.
6. Yamamoto N, Bauer G. Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation. Med Hypotheses, 2020, 144: 110160.
7. 中華醫學會呼吸病學分會, 中國醫師協會呼吸醫師分會. 中國成人2019冠狀病毒病的診治與防控指南. 中華醫學雜志, 2021, 101(18): 1293-1356.
8. Islam OK, Al-Emran HM, Hasan MS, et al. Emergence of European and North American mutant variants of SARS-CoV-2 in South-East Asia. Transbound Emerg Dis, 2021, 68(2): 824-832.
9. Leung K, Shum MH, Leung GM, et al. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill, 2021, 26(1): 2002106.
10. Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol, 2020, 127: 104378.
11. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ, 2020, 369: m1985.
12. 陳竹, 毛毅, 陳霆, 等. 成都379例新型冠狀病毒肺炎的臨床分析. 中國胸心血管外科臨床雜志, 2021, 28(4): 388-395.
13. Joyce KE, Weaver SR, Lucas SJE. Geographic components of SARS-CoV-2 expansion: A hypothesis. J Appl Physiol (1985), 2020, 129(2): 257-262.
14. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1): 73-84.
15. 郝耀梅, 任建業. 慢性病患者用藥依從性管理案例分析. 中國藥物與臨床, 2021, 21(4): 685-686.
16. Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China: Results from the china hypertension survey, 2012-2015. Circulation, 2018, 137(22): 2344-2356.
17. Nikolich-?ugich J. The twilight of immunity: Emerging concepts in aging of the immune system. Nat Immunol, 2018, 19(1): 10-19.
18. Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: An observational cohort study. Lancet, 2020, 396(10251): 603-611.
19. 李聞, 鄭寶璐, 于愛萍, 等. 新型冠狀病毒IgM/IgG抗體在病程監測中的臨床意義. 臨床檢驗雜志, 2020, 38(6): 401-404.
20. 馬春娜, 吳雙勝, 孫瑛, 等. 2020年1~7月北京市不同階段新型冠狀病毒肺炎疫情特征分析. 國際病毒學雜志, 2020, 27(6): 448-454.
21. 陳晴, 黃濤, 楊銘, 等. 成都市不同年齡段新型冠狀病毒肺炎患者臨床特征及預后分析. 實用心腦肺血管病雜志, 2020, 28(12): 9-15.
22. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev, 2020, 6(6): CD013652.
23. Shi P, Ren G, Yang J, et al. Clinical characteristics of imported and second-generation coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: A multicentre retrospective study. Epidemiol Infect, 2020, 148: e238.
24. 代嫣嫣, 夏帥, 王茜, 等. 人類高致病性冠狀病毒SARS-CoV和MERS-CoV的流行與突變—共性與個性特征的啟示. 生命科學, 2016, 28(3): 357-366.
25. Khan MI, Khan ZA, Baig MH, et al. Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight. PLoS One, 2020, 15(9): e0238344.
26. Rabaan AA, Al-Ahmed SH, Sah R, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Ann Clin Microbiol Antimicrob, 2020, 19(1): 40.
27. Dhama K, Patel SK, Pathak M, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis, 2020, 37: 101755.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Clinical characteristics of overseas imported and related local COVID-19 patients in Chengdu

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content